دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
Robert J. Mentz, MD,a Jonathan H. Ward, P HARMD, b Adrian F. Hernandez, MD, MHS, a Serge Lepage, MD,c David A. Morrow, MD, MPH,d Samiha Sarwat, PHD, b Kavita Sharma, MD, e Randall C. Starling, MD, MPH, f Eric J. Velazquez, MD,g Kristin M. Williamson, PHARMD, b Akshay S. Desai, MD, MPH,d Shelley Zieroth, MD, h Scott D. Solomon, MD, d Eugene Braunwald, MD, d on behalf of the PARAGLIDE-HF Investigators
doi : 10.1016/j.jacc.2023.04.019
Volume 82, Issue 1, 4 July 2023, Pages 1-12
Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some∗
Hector O. Ventura, MD,a Carl J. Lavie, MD, a Mandeep R. Mehra, MD, MS
doi : 10.1016/j.jacc.2023.05.002
Volume 82, Issue 1, 4 July 2023, Pages 13-15
Long-Term Outcomes of Women With Peripartum Cardiomyopathy Having Subsequent Pregnancies
Pavida Pachariyanon, MD,a Hari Bogabathina, MD, a Keerthish Jaisingh, MD, a Morni Modi, BS, MS, b Kalgi Modi, MD
doi : 10.1016/j.jacc.2023.04.043
Volume 82, Issue 1, 4 July 2023, Pages 16-26
Long-term maternal outcomes of subsequent pregnancies (SSPs) in patients with peripartum cardiomyopathy (PPCM) have not been analyzed.
Safety of Subsequent Pregnancy After Recovery From Peripartum Cardiomyopathy∗
Uri Elkayam, MD
doi : 10.1016/j.jacc.2023.04.042
Volume 82, Issue 1, 4 July 2023, Pages 27-29
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results
Valentina Yu. Myachikova, MD,a,b Alexey L. Maslyanskiy, MD, P HD, b,c Olga M. Moiseeva, MD, PHD, d Oksana V. Vinogradova, MD,e Ekaterina V. Gleykina, MD, f Yan Lavrovsky, MD, PHD, g Antonio Abbate, MD, P HD, h Sergey A. Grishin, MD, PHD, i Alina N. Egorova, MD, i Margarita L. Schedrova, PHARMD, i Mikhail Yu. Samsonov, MD, PH D
doi : 10.1016/j.jacc.2023.04.046
Volume 82, Issue 1, 4 July 2023, Pages 30-40
Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor—goflikicept in IRP.
Recurrent Pericarditis: A Promising Future for IL-1 Blockers in Autoinflammatory Phenotypes∗
Allan L. Klein, MD, Paul C. Cremer, MD, MS, Tahir S. Kafil, MD
doi : 10.1016/j.jacc.2023.05.013
Volume 82, Issue 1, 4 July 2023, Pages 41-45
Cognitive Behavioral Therapy Improves Quality of Life in Patients With Symptomatic Paroxysmal Atrial Fibrillation
Josefin S?rnholm, P HD, a Helga Sk?lad?ttir, MD,b,c Christian Rück, MD, P HD, d,e Erland Axelsson, P HD, a,f,g,h Marianne Bonnert, P HD, d,e,i Maria Bragesj?, PH D, a Ashwin Venkateshvaran, PH D, b,c Eva ?lafsd?ttir, RN,b,c Susanne S. Pedersen, PH D, j,k Brj?nn Lj?tsson, PH D, a, * Frieder Braunschweig, MD, P HD
doi : 10.1016/j.jacc.2023.04.044
Volume 82, Issue 1, 4 July 2023, Pages 46-56
Atrial fibrillation (AF) is often associated with troubling symptoms leading to impaired quality of life (QoL) and high health care use. Symptom preoccupation, that is, fear of cardiac-related symptoms and avoidance behavior, potentially contributes to disability in AF but is not targeted by current interventions.
Beyond Drugs and Ablation: New Hope for Symptom Management in Patients With Paroxysmal Atrial Fibrillation?∗
Pamela J. McCabe, PHD, APRN-CNS
doi : 10.1016/j.jacc.2023.05.007
Volume 82, Issue 1, 4 July 2023, Pages 57-59
Single Troponin Measurement to Rule Out Myocardial Infarction: JACC Review Topic of the Week
Allan S. Jaffe, MD, a,b Richard Body, MD,c,d,e Nicholas L. Mills, MD,f,g Kristin M. Aakre, PH D, h,i,j Paul O. Collinson, MD, k,l,m Amy Saenger, PH D, n,o Ole Hammarsten, MD,p Ryan Wereski, MD, f Torbj?rn Omland, MD,q,r Yader Sandoval, MD, s Jordi Ordonez-Llanos, MD, PHD, t,u Fred S. Apple, P HD, n,o on behalf of the IFCC Committee on Cardiac Bio-Markers
doi : 10.1016/j.jacc.2023.04.040
Volume 82, Issue 1, 4 July 2023, Pages 60-69
The term “single-sample rule-out� refers to the ability of very low concentrations of high-sensitivity cardiac troponin (hs-cTn) on presentation to exclude acute myocardial infarction with high clinical sensitivity and negative predictive value. Observational and randomized studies have confirmed this ability.
Adverse Hemodynamic Consequences of Continuous Left Ventricular Mechanical Support: JACC Review Topic of the Week
Jonathan Grinstein, MD, a Mark N. Belkin, MD,a Sara Kalantari, MD,a Kevin Bourque, MSME, b Christopher Salerno, MD, c Sean Pinney, MD
doi : 10.1016/j.jacc.2023.04.045
Volume 82, Issue 1, 4 July 2023, Pages 70-81
Left ventricular assist devices (LVADs) provide lifesaving therapy for patients with advanced heart failure. The recognition of pump thrombosis, stroke, and nonsurgical bleeding as hemocompatibility-related adverse events (HRAEs) led to pump design improvements and reduced adverse event rates
Evolving Cardiovascular Education in a Postpandemic World
Douglas E. Drachman, MD, FACC, ACC Annual Scientific Session Chair Cathleen C. Gates, ACC Chief Executive Officer Jane A. Linderbaum, ARNP, CNP, FACC, Immediate Past ACC Annual Scientific Session CV Team Lead
doi : 10.1016/j.jacc.2023.05.033
Volume 82, Issue 1, 4 July 2023, Pages 82-84
Postprocedural Coronary Perfusion and Mortality in Patients With Acute Myocardial Infarction and Extracorporeal Cardiopulmonary Resuscitation
Takahiro Nakashima, MD, PhD Takayuki Otani, MD Shunichi Kato, MD Marina Arai, MD Akihiko Inoue, MD, PhD Toru Hifumi, MD, PhD Tetsuya Sakamoto, MD, PhD Yasuhiro Kuroda, MD, PhD Yoshio Tahara, MD, PhD
doi : 10.1016/j.jacc.2023.04.041
Volume 82, Issue 1, 4 July 2023, Pages 85-87
